
Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the twice-yearly injection into doubt.
See omnystudio.com/listener for privacy information.

Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the twice-yearly injection into doubt.
See omnystudio.com/listener for privacy information.